- A phase III study for Johnson & Johnson's (JNJ) Paliperidone Palmitate 3-month formulation for schizophrenia has been stopped early due to the drug's effectiveness in delaying relapse when compared with a placebo.
- The data is now set to be unblinded.
- J&J unit Janssen, which developed the drug, plans to file for FDA approval of the treatment by the end of the year. (PR)
Trial for J&J schizophrenia drug stopped early due to efficacy
From other sites
at 4-traders.com (Tue, 12:37PM)
at Nasdaq.com (Mar 16, 2015)
at Nasdaq.com (Mar 11, 2015)
at Benzinga.com (Feb 23, 2015)
at Nasdaq.com (Feb 19, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs